Stock Market

Exact Sciences (NASDAQ:EXAS) reported results for the first quarter of 2023.

  • Exact Sciences reported a loss per share of 42 cents. That is much better than the analyst estimate for a loss of 75 cents per share.
  • The company reported revenue of $602.45 million.
  • This represents 10.8% positive surprise against the analyst estimate of $543.46 million.
  • You can read the full Exact Sciences press release here.

On the date of publication, Sarah Smith did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Sarah Smith is the Editor-in-Chief of InvestorPlace.com.

Articles You May Like

Apple Intelligence: Redefining AI With the Ultimate Assistant
The Fed Just Opened a Door to Stunning Stock Gains
Rate Cuts to Energize Markets, Score Investors Tremendous Profits
Your favorite stocks may soon be quoted in half-penny increments – which could cut trading costs
Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors